More On

Teva to pay $250 million to end hepatitis C cases

Plaintiffs say they became infected when doctors reused large vials of Propofol

One pharmaceutical company recently learned that it shouldn’t exactly embrace the Earth-friendly mantra “reduce, reuse, recycle.”

Last week Teva Pharmaceutical Industries Ltd. agreed to pay more than $250 million to settle more than 80 lawsuits in which colonoscopy patients from Las Vegas claim the company’s anesthetic Propofol caused them to develop the liver disease hepatitis C. The plaintiffs claimed the Israel-based drug company intentionally sold the drug in oversize vials that doctors used for multiple patients, thus increasing the risk of spreading the incurable blood-borne disease.

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.